Abstract:Vector capsid dose-dependent inflammation of transduced liver has limited the ability of adeno-associated virus (AAV) factor IX (FIX) gene therapy vectors to reliably convert severe to mild hemophilia B in human clinical trials. These trials also identified the need to understand AAV neutralizing antibodies and empty AAV capsids regarding their impact on clinical success. To address these safety concerns, we have used a scalable manufacturing process to produce GMP-grade AAV8 expressing the FIXR338L gain-of-function variant with minimal (<10%) empty capsid and have performed comprehensive dose-response, biodistribution, and safety evaluations in clinically relevant hemophilia models. The scAAV8.FIXR338L vector produced greater than 6-fold increased FIX specific activity compared with wild-type FIX and demonstrated linear dose responses from doses that produced 2-500% FIX activity, associated with dose-dependent hemostasis in a tail transection bleeding challenge. More importantly, using a bleeding model that closely mimics the clinical morbidity of hemophilic arthropathy, mice that received the scAAV8.FIXR338L vector developed minimal histopathological findings of synovitis after hemarthrosis, when compared with mice that received identical doses of wild-type FIX vector. Hemostatically normal mice (n=20) and hemophilic mice (n=88) developed no FIX antibodies after peripheral intravenous vector delivery. No CD8(+) T cell liver infiltrates were observed, despite the marked tropism of scAAV8.FIXR338L for the liver in a comprehensive biodistribution evaluation (n=60 animals). With respect to the role of empty capsids, we demonstrated that in vivo FIXR338L expression was not influenced by the presence of empty AAV particles, either in the presence or absence of various titers of AAV8-neutralizing antibodies. Necropsy of FIX(-/-) mice 8-10 months after vector delivery revealed no microvascular or macrovascular thrombosis in mice expressing FIXR338L (plasma FIX activity, 100-500%). These preclinical studies demonstrate a safety:efficacy profile supporting an ongoing phase 1/2 human clinical trial of the scAAV8.FIXR338L vector (designated BAX335).

Safety Assessment of Intramuscular Administration of Recombinant Adeno-associated Virus(AAV)-mFIX

Preparation of Raav/hflx by HSV/AAV Hybrid Helper Virus and Evaluation of Its Safety

Muscle Injection of Raav/mfix to Secrete Clotting Factor IX Corrects the Hemorrhagic Tendencies in Hemophilia B Mice

The Safety Assessment of Gene Transfer Mediated by the New Recombinant Adeno-Associated Virus Serotype 1 Pseudotyped Vector in Mouse Ischemic Lamb Model

Gene Therapy for Hemophilia B Mediated by Recombinant Adeno-Associated Viral Vector with Hfixr338a,a High Catalytic Activity Mutation of Human Coagulation Factor IX

Preparation of A Recombinant Adeno-Associated Viral Vector with A Mutation of Human Factor Ix in Large Scale and Its Expression in Vitro and in Vivo

Skeletal Muscle-Specific Expression of Human Blood Coagulation Factor IX Rescues Factor IX Deficiency Mouse by AAV-mediated Gene Transfer.

[Preparation of Raav2/hfix and Experimentally Application to Gene Therapy for Hemophilia B].

Gene Therapy for Hemophilia B in Immature Mice Using ScAAV-DJ/8-LP1-hFIXco Vector

Long-term correction of hemorrhagic diathesis in hemophilia A mice by an AAV-delivered hybrid FVIII composed of the human heavy chain and the rat light chain

Gene Therapy for Hemophilia B Mice with Scaav8-Lp1-hfix

Employing a Gain-of-Function Factor IX Variant R338L to Advance the Efficacy and Safety of Hemophilia B Human Gene Therapy: Preclinical Evaluation Supporting an Ongoing Adeno-Associated Virus Clinical Trial

Direct Intrathecal Injection of Recombinant Adeno-associated Viruses in Adult Mice.

A Study of Gene Transfer and Expression of Human Clotting Factor IX in Hemophilia B Mice Mediated by Mini-Adenoviral Vector.

Protection against duck hepatitis a virus type 1 conferred by a recombinant avian adeno-associated virus

High-efficiency Transduction and Correction of Murine Hemophilia B Using AAV2 Vectors Devoid of Multiple Surface-exposed Tyrosines

The Glymphatic System Delivery Enhances the Transduction Efficiency of AAV1 to Brain Endothelial Cells in Adult Mice.

Immune responses to AAV in clinical trials

Sustaining Expression of B Domain-Deleted Human Factor VIII Mediated by Using Lentiviral Vectors in NOD/SCID Mouse.

Adeno‐associated Virus Vectors for Gene Therapy—focusing on Melanoma

Development of a Clinical Candidate AAV3 Vector for Gene Therapy of Hemophilia B.